Evidence map›Paper›PMID 25885064›Full record

ArticleBMC cancer2015

The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.

Julie Steinestel, Andreas Al Ghazal, Annette Arndt, Thomas J Schnoeller, Andres J Schrader, Peter Moeller, Konrad Steinestel

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Prevalence of the most common types of high-risk HPV and p16Postepy dermatologii i alergologii · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Prognostic Markers and Trials in Penile Cancer.Urology research & practice · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Immune-based therapies in penile cancer.Nature reviews. Urology · 2022
    Review
  17. Review
  18. Article
  19. An update on treatment of penile cancer.Therapeutic advances in medical oncology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Julie SteinestelDepartment of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1, A1, 48149, Muenster, Germany. julie@steinestel.com.
Andreas Al GhazalDepartment of Urology, University of Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany. andreas.alghazal@uniklinik-ulm.de.
Annette ArndtInstitute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081, Ulm, Germany. annettearndt@bundeswehr.org.
Thomas J SchnoellerDepartment of Urology, University of Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany. thomas.schnoeller@uniklinik-ulm.de.
Andres J SchraderDepartment of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1, A1, 48149, Muenster, Germany. ajschrader@gmx.de.
Peter MoellerInstitute of Pathology, University of Ulm, Albert-Einstein-Allee 23, 89070, Ulm, Germany. peter.moeller@uniklinik-ulm.de.
Konrad SteinestelGerhard Domagk Institute of Pathology, University of Muenster, Domagkstrasse 17, 48149, Muenster, Germany. konrad@steinestel.com.
Universität Ulm · DEBundeswehrkrankenhaus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUp to 50% of penile squamous cell carcinomas (pSCC) develop in the context of high-risk human papillomavirus (HR-HPV) infection. Most of these tumours have been reported to show basaloid differentiation and overexpression of tumour suppressor protein p16(INK4a). Whether HPV-triggered carcinogenesis in pSCC has an impact on tumour aggressiveness, however, is still subject to research.

methodsIn tissue specimens from 58 patients with surgically treated pSCC between 1995 and 2012, we performed p16(INK4a) immunohistochemistry and DNA extraction followed by HPV subtyping using a PCR-based approach. The results were correlated with histopathological and clinical parameters.

results90.4% of tumours were of conventional (keratinizing) subtype. HR-HPV DNA was detected in 29.3%, and a variety of p16(INK4a) staining patterns was observed in 58.6% of samples regardless of histologic subtype. Sensitivity of basaloid subtype to predict HR-HPV positivity was poor (11.8%). In contrast, sensitivity and specificity of p16(INK4a) staining to predict presence of HR-HPV DNA was 100% and 57%, respectively. By focussing on those samples with intense nuclear staining pattern for p16(INK4a), specificity could be improved to 83%. Both expression of p16(INK4a) and presence of HR-HPV DNA, but not histologic grade, were inversely associated with pSCC tumour invasion (p = 0.01, p = 0.03, and p = 0.71). However, none of these correlated with nodal involvement or distant metastasis. In contrast to pathological tumour stage, the HR-HPV status, histologic grade, and p16(INK4a) positivity failed to predict cancer-specific survival.

conclusionsOur results confirm intense nuclear positivity for p16(INK4a), rather than histologic subtype, as a good predictor for presence of HR-HPV DNA in pSCC. HR-HPV / p16(INK4a) positivity, independent of histological tumour grade, indicates a less aggressive local behaviour; however, its value as an independent prognostic indicator remains to be determined. Since local invasion can be judged without p16(INK4a)/HPV-detection on microscopic evaluation, our study argues against routine testing in the setting of pSCC.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16DNA, ViralGene ExpressionGenotypeHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm StagingPapillomaviridaeCyclin-Dependent Kinase Inhibitor p16DNA, Viral

Identifiers

PMID25885064
PMCPMC4392470
OpenAlexW2005367766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.